Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.08T
Market cap1.08T
Price-Earnings ratio
38.83
Price-Earnings ratio38.83
Dividend yield
0.59%
Dividend yield0.59%
Average volume
2.27M
Average volume2.27M
High today
$1,164.92
High today$1,164.92
Low today
$1,136.66
Low today$1,136.66
Open price
$1,152.26
Open price$1,152.26
Volume
2.05M
Volume2.05M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$783.85
52 Week low$783.85

Stock Snapshot

With a market cap of 1.08T, Eli Lilly(LLY) trades at $1,143.60. The stock has a price-to-earnings ratio of 38.83 and currently yields dividends of 0.59%.

During the trading session on 2026-10-03, Eli Lilly(LLY) shares reached a daily high of $1,164.92 and a low of $1,136.66. At a current price of $1,143.60, the stock is +0.6% higher than the low and still -1.8% under the high.

Trading activity shows a volume of 2.05M, compared to an average daily volume of 2.27M.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

LLY News

Simply Wall St 13h
Eli Lilly Posts Drug Trial Wins As Pipeline Progress Meets Legal Setbacks

Eli Lilly (NYSE:LLY) reported new clinical data on obesity drug Foundayo, diabetes candidate EloraTZP, and dermatitis therapy EBGLYSS, alongside plans for regul...

Eli Lilly Posts Drug Trial Wins As Pipeline Progress Meets Legal Setbacks
TipRanks 21h
Eli Lilly announces FDA approves additional indication for Jaypirca

Eli Lilly (LLY) and Company announced that the U.S. Food and Drug Administration FDA has approved an additional indication for Jaypirca, a non-covalent Bruton t...

24/7 Wall St. 1d
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker

Investing Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching...

Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

Zacks 1d
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies

Eli Lilly and Company (LLY Quick QuoteLLY - Free Report) presented new efficacy data from studies of its marketed and investigational metabolic medicines...

LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
TipRanks 1d
Wedbush downgrades Foghorn on end of Lilly collaboration

Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform with a price target of $2, down from $10, after the company and Eli Lilly (LLY) electe...

The Motley Fool 2d
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?

Choosing between the diversified stability of Johnson & Johnson (JNJ -2.30%) and the rapid growth trajectory of Eli Lilly & Co (LLY -0.63%) is a primary conside...

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
The Motley Fool 2d
Could Eli Lilly's Newest Weight Loss Strategy Pay Off for Decades?

Eli Lilly (LLY -0.61%) has emerged as the leader in the weight-loss market and is posting excellent financial results, partly thanks to its position in this are...

Could Eli Lilly's Newest Weight Loss Strategy Pay Off for Decades?
Benzinga 2d
Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk

Eli Lilly and Co. (NYSE:LLY) on Thursday announced post-hoc analyses from its ATTAIN-1 study alongside detailed Phase 3 ACHIEVE-4 trial results. The findings d...

Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk
Benzinga 2d
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 tho...

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
TipRanks 2d
Eli Lilly Ends Cancer Development Deal with Foghorn Therapeutics

Pharmaceutical giant Eli Lilly (LLY) has ended a deal it had in place to develop cancer treatments with Foghorn Therapeutics (FHTX). News of the agreement’s can...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.